Physician profile
Satvir Singh
NPI 1114969052
$20,306.34
in general payments reported to CMS, 2019-2025
55 companies · $6,997 in 2025
The $6,997 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $620 · 2021: $3,580 · 2022: $428 · 2023: $6,212 · 2024: $2,272 · 2025: $6,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,149 · Consulting Fee: $6,668 · Travel and Lodging: $1,298 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,149.46 |
| Consulting Fee | $6,668.00 |
| Travel and Lodging | $1,297.64 |
| Education | $365.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,568.79 | 2021-2025 | Tagrisso, Imfinzi, Lynparza |
| Incyte Corporation | $5,088.41 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Exelixis INC. | $1,351.70 | 2020-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $1,335.50 | 2021-2025 | Opdivo, Augtyro |
| Beigene, LTD. | $975.00 | 2020-2021 | |
| Pfizer INC. | $915.38 | 2020-2025 | |
| Seagen INC. | $710.54 | 2019-2023 | Adcetris, Tivdak, Tukysa |
| Glaxosmithkline, LLC. | $517.76 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $423.79 | 2021-2025 | Tecentriq, Alecensa, Polivy |
| Astellas Pharma US INC | $335.88 | 2022-2025 | Padcev, Veozah, Xtandi |
| Genzyme Corporation | $313.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $301.82 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $200.04 | 2020-2025 | |
| Celgene Corporation | $199.03 | 2019-2025 | Opdualag, Reblozyl, Opdivo |
| Abbvie INC. | $195.16 | 2024-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $175.95 | 2023-2025 | Rybrevant, Imbruvica, Darzalex |
| Array Biopharma INC | $119.10 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Lilly USA, LLC | $96.39 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $89.24 | 2021-2025 | Trodelvy |
| Deciphera Pharmaceuticals INC. | $88.48 | 2023-2025 | Qinlock, Romvimza, Tgct |
| Ipsen Biopharmaceuticals, INC | $68.31 | 2023-2024 | Onivyde |
| Beone Medicines USA, INC. | $68.21 | 2025 | Tevimbra, Brukinsa |
| Amgen INC. | $67.66 | 2020-2023 | Lumakras, Vectibix, Nplate |
| Jazz Pharmaceuticals INC. | $66.62 | 2023-2025 | |
| Stemline Therapeutics INC. | $65.85 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $62.37 | 2025 | Fruzaqla, Ninlaro |
| Daiichi Sankyo INC. | $60.27 | 2024-2025 | Enhertu |
| Dendreon Pharmaceuticals LLC | $57.08 | 2024 | Provenge |
| Pharmacyclics LLC, An Abbvie Company | $55.52 | 2022-2023 | Imbruvica, Epkinly |
| Puma Biotechnology, INC. | $52.94 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.08 | 2022-2025 | |
| Adc Therapeutics America, INC. | $51.66 | 2024-2025 | |
| Mirati Therapeutics, INC. | $50.74 | 2023-2024 | Krazati |
| Adaptive Biotechnologies Corporation | $45.47 | 2024 | Clonoseq |
| Beigene USA, INC. | $42.52 | 2023-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $41.27 | 2022-2023 | Libtayo |
| Coherus Oncology, INC. | $40.63 | 2022-2024 | |
| Cti Biopharma Corp. | $31.73 | 2023 | Vonjo |
| Sobi, INC | $26.21 | 2025 | |
| Emd Serono, INC. | $22.26 | 2024 | |
| G1 Therapeutics, INC. | $22.19 | 2023 | Cosela |
| Insmed, INC. | $22.05 | 2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $21.69 | 2024 | Ultomiris |
| Eisai INC. | $21.50 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.02 | 2022 | |
| Tempus Ai, INC | $18.79 | 2025 | Xt Cdx |
| Acrotech Biopharma INC. | $18.23 | 2024 | Beleodaq |
| Agios Pharmaceuticals, INC. | $17.84 | 2023 | Pyrukynd |
| Csl Behring | $17.37 | 2023 | Hizentra |
| Helsinn Therapeutics (U.S.), INC. | $16.41 | 2023 | Akynzeo |
| Immunogen, INC. | $15.99 | 2024 | Elahere |
| Kite Pharma, INC. | $15.44 | 2023 | Yescarta |
| Novocure INC. | $14.95 | 2025 | Optune Lua (Novottf-200t) |
| Emmaus Medical, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satvir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.